Position in SLN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,215,039
+$1,145,751 QoQ
Shares Held
201,734
-0.6% QoQ
Ownership
0.325%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#22
of 72 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in SLN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BANK OF MONTREAL /CAN/ holds $701,516,965 across 82 Biotechnology names. SLN ranks #25 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
427,448 | $212,326,240 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
942,432 | $73,764,150 | |
| 3 | ARGX |
Argenx SE
|
77,213 | $71,635,902 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
103,247 | $64,378,631 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
242,063 | $58,329,919 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
515,981 | $28,347,995 | |
| 7 | MRNA |
Moderna, Inc.
|
389,789 | $27,296,921 | |
| 8 | CYTK |
Cytokinetics Inc
|
285,688 | $24,337,759 |
All Filings in SLN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,215,039 | 201,734 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $1,069,288 | 202,901 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $975,681 | 160,474 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $798,128 | 153,782 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $845,709 | 145,812 | Shares | Defined | 2025-08-05 | |
| 2025-03-31 | $447,232 | 158,593 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $447,248 | 65,007 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $1,186,408 | 65,259 | Shares | Defined | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||